How should I interpret and manage labs showing anion gap 10.9, eGFR 59 mL/min/1.73 m², MCHC 31.4 g/dL, and MPV 12.5 fL?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Lab Review: Interpretation and Management

Your labs show Stage 3a chronic kidney disease (CKD) with moderate renal insufficiency (eGFR 59 mL/min/1.73 m²), while the anion gap of 10.9 is actually normal by modern measurement standards, and the MCHC/MPV findings are minor red blood cell variations that require no immediate action.

eGFR 59 mL/min/1.73 m² - Stage 3a CKD

This is the most clinically significant finding requiring action.

Classification and Risk

Your eGFR places you in Stage 3a CKD (moderately decreased GFR: 45-59 mL/min/1.73 m²) 1. According to KDIGO classification, without knowing your albuminuria status, you fall into at minimum the "moderate risk" category 1.

Required Actions:

  • Check urine albumin-to-creatinine ratio (UACR) immediately if not already done - this is essential for complete risk stratification 2, 3
  • Annual monitoring minimum: Repeat eGFR and UACR at least once yearly, potentially more frequently depending on progression rate 4
  • Blood pressure control: Target <140/90 mmHg 5
  • Consider nephrology referral if: UACR >60 mg/mmol, evidence of progression (>5 mL/min/1.73 m² decline per year), or drop to eGFR <45 mL/min/1.73 m² 2, 5

Medication Considerations:

  • Review all medications for renal dosing adjustments - many drugs require dose modification at eGFR <60 5
  • If you have diabetes and/or albuminuria, ACE inhibitors or ARBs are preferred for blood pressure management 3
  • Consider SGLT-2 inhibitors if you have diabetes or significant albuminuria, as these reduce CKD progression and cardiovascular events 1, 2

Monitoring for Progression:

Watch for decline in GFR category with ≥25% drop from baseline, or rapid progression defined as sustained decline >5 mL/min/1.73 m²/year 4, 5. Small fluctuations are common and don't necessarily indicate true progression 4.

Anion Gap 10.9 - NORMAL

This is not high. Modern ion-selective electrode methodology has shifted the normal anion gap reference range from the old 12±4 mEq/L down to 3-11 mEq/L or 6±3 mEq/L 6, 7, 8. Your value of 10.9 falls within the current normal range.

Key Point:

Many clinicians and older textbooks still reference the outdated range of 8-16 mEq/L, leading to misinterpretation 7. A truly elevated anion gap by modern standards would be >12 mEq/L, with values >24 mEq/L being rare and highly significant 7. Your value requires no intervention.

MCHC 31.4 g/dL (Low) and MPV 12.5 fL (High)

MCHC (Mean Corpuscular Hemoglobin Concentration):

Low MCHC typically indicates hypochromic anemia, most commonly from iron deficiency. However, at Stage 3a CKD, anemia screening is not routinely recommended until eGFR drops below 30 mL/min/1.73 m² 9.

Action needed:

  • Check complete blood count with hemoglobin level
  • If anemic (hemoglobin low), check: serum ferritin, transferrin saturation (TSAT), vitamin B12, and folate 9
  • Iron supplementation trial warranted if TSAT ≤30% and ferritin ≤500 ng/mL 9

MPV (Mean Platelet Volume):

Mildly elevated MPV (12.5 fL) is a non-specific finding that can occur with platelet activation, inflammation, or as a normal variant. In isolation without thrombocytopenia or thrombocytosis, this requires no specific action.

Priority Action Plan:

  1. Obtain UACR to complete CKD risk stratification
  2. Review current medications for renal dose adjustments
  3. Check blood pressure - ensure <140/90 mmHg
  4. Verify hemoglobin level - if low, proceed with anemia workup
  5. Schedule annual follow-up for eGFR and UACR monitoring
  6. Consider nephrology referral if UACR elevated or eGFR declining

The anion gap is normal and requires no action. Focus clinical attention on the Stage 3a CKD and its management.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.